Circulating tumor cells (CTC) market is expected to grow over the forecast period owing to the increasing prevalence of cancer and growing population. The other growth drivers of this market are introduction of technological advancements such as hybrid method of synthesis of peptides, lifestyle induced diseases such as obesity & diabetes, sophisticated healthcare infrastructure, increasing population and awareness. These factors are expected to drive the market over the forecast period. Cancer is disease caused by abnormal cell growth and has possibility to spread to other parts of the body too. The symptoms or sign are such as change in bowel movements, unexplained weight loss, prolonged cough, abnormal bleeding, and new lump. For deciding the procedure of treatment cancer prognosis plays a vital role. Under liquid biopsy, biomarker is preferred more than other tissue biopsy procedures, as it follows minimally invasive procedure. Increasing incidences of cancer induced lifestyle habits such as continuous exposure to UV, lack of exercise, dietary habits, excessive alcohol consumption, smoking and chewing tobacco. Complex isolation of tumor cells is anticipated to restraining the market over the upcoming five years.
CTC market is segmented on the basis of technology into tumor cell enrichment & detection, molecular, optical, and immunological and immunomagnetic, centrifugation, filtration. Among these, tumor cell enrichment & detection held the largest market share in 2013, owing to relatively friendly operation, faster outcome availability, easy sample collection, and high accuracy level. Tumor cell enrichment & detection technology market over the forecast period is anticipated to rise at a CAGR of 27%. Over the upcoming five years immunological & immunomagnetic technology market will witness fastest CAGR, owing to its operation with all genome sequencing and its effective analysis along with lesser blood sample. Additionally, R & D is anticipated to boost the market over the forecast period.
CTC market is segmented on the basis of application into breast cancer, colorectal cancer, and prostate cancer. Among these, breast cancer held the largest market share in 2013 due to generation of circulatory tumor cells from small primary tumors and higher frequency of malignancy. Metastasis in incidental vital organs is the main reason for cancer fatality. As per the report publish by WHO in 2017, it says that 8.5 million death occurs due to cancer, out of that 9.0% is liver constituted, 8.5% is constituted by breast cancer, and 8.4% is constituted by colorectal cancer.
Geographically, the CTC market is studied with respect to four regions such as Asia Pacific, Europe, North America, and RoW. Among these, North America is dominating the whole market in 2017, as it has presence of technologically updated systems, strong research & development, various government initiatives & programs and high patient awareness levels in this region. The growing economies in Asia Pacific such as India and China region are expected to witness lucrative growth over the forecast period owing to the rising healthcare expenditure, and awareness about the hospital acquired infection.
The major market players in the circulating tumor cells market are Advanced Cell Diagnostics Inc., Veridex, LLC., Vitatex Inc., AdnaGen AG, AVIVA BioSciences Corporation and Silicon Biosystems.
Research Support Specialist, USA